Form 4: Definitive Healthcare CFO Casey Heller Reports Significant RSU Grant

Definitive Healthcare Corp.'s Chief Financial Officer, Casey Heller, reported the acquisition of 485,881 restricted stock units (RSUs) on June 10, 2025, increasing her beneficial ownership to over 1 million shares.

Summary

• Casey Heller, Chief Financial Officer of Definitive Healthcare Corp. (DH), reported the acquisition of 485,881 shares of Class A Common Stock.
• The acquisition was in the form of Restricted Stock Units (RSUs) granted at a price of $0.
• The RSUs have a vesting schedule: 25% will vest on June 1, 2026, followed by 6.25% vesting every three months thereafter over the subsequent three years.
• Vesting is contingent upon Ms. Heller's continued service with Definitive Healthcare Corp. through each vesting date.
• Following this transaction, Ms. Heller's total beneficial ownership of Class A Common Stock is 1,090,965 shares.

Sentiment

Score: 7

Explanation: The grant of a significant number of Restricted Stock Units (RSUs) to the Chief Financial Officer is generally a positive indicator of executive retention and alignment with long-term shareholder value. It is a standard compensation event and does not reflect immediate operational or financial performance changes, hence a moderately positive score.

Positives

• The grant of a significant number of Restricted Stock Units (RSUs) to the Chief Financial Officer aligns management's long-term interests with shareholder value creation.
• Equity compensation serves as a strong incentive for executive retention and performance.

Risks

• The vesting of the Restricted Stock Units (RSUs) is subject to the Reporting Person's continued service with the Issuer, meaning the shares could be forfeited if employment ceases before vesting dates.

Future Outlook

The multi-year vesting schedule for the granted Restricted Stock Units (RSUs) indicates a long-term retention strategy for the Chief Financial Officer, aligning her incentives with the company's sustained performance over the coming years.

Industry Context

The use of Restricted Stock Units (RSUs) as a form of executive compensation is a common practice across various industries, including the healthcare technology sector, to attract, retain, and incentivize key management personnel by aligning their financial interests with the long-term performance of the company.

Comparison to Industry Standards

• Equity grants, such as Restricted Stock Units (RSUs) with multi-year vesting schedules, are a standard component of executive compensation packages in publicly traded companies, including those in the healthcare technology industry.
• The specific size of the grant (485,881 RSUs) would typically be benchmarked against grants to CFOs at companies of similar market capitalization, revenue, and growth stage within the healthcare IT or SaaS sectors, though specific comparable companies or projects are not detailed in this filing.

Stakeholder Impact

• Shareholders: The RSU grant aligns the Chief Financial Officer's financial incentives with the long-term performance and value creation for shareholders.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• Continued vesting of the granted Restricted Stock Units (RSUs) according to the specified schedule (25% on June 1, 2026, and 6.25% every three months thereafter for three years), subject to continued service.

Key Dates

Recommendation

Keywords

Definitive Healthcare, DH, Casey Heller, Chief Financial Officer, CFO, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Beneficial Ownership, SEC Form 4